Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating)'s share price was up 4.8% during trading on Wednesday after an insider bought additional shares in the company. The company traded as high as $163.59 and last traded at $163.21. Approximately 8,426 shares traded hands during trading, a decline of 98% from the average daily volume of 370,576 shares. The stock had previously closed at $155.67.

Specifically, CEO August J. Troendle purchased 8,330 shares of the firm's stock in a transaction that occurred on Monday, July 18th. The shares were acquired at an average price of $145.00 per share, with a total value of $1,207,850.00. Following the purchase, the chief executive officer now directly owns 5,513,639 shares in the company, valued at $799,477,655. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Medpace news, CEO August J. Troendle acquired 8,330 shares of the business's stock in a transaction on Monday, July 18th. The stock was purchased at an average price of $145.00 per share, for a total transaction of $1,207,850.00. Following the transaction, the chief executive officer now owns 5,513,639 shares in the company, valued at approximately $799,477,655. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle acquired 22,290 shares of the business's stock in a transaction on Thursday, July 14th. The stock was acquired at an average price of $144.59 per share, with a total value of $3,222,911.10. Following the transaction, the chief executive officer now owns 5,505,309 shares in the company, valued at approximately $796,012,628.31. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 368,843 shares of company stock valued at $57,662,959. 20.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on MEDP shares. UBS Group started coverage on Medpace in a research note on Wednesday, September 7th. They issued a "sell" rating and a $142.00 target price for the company. StockNews.com cut Medpace from a "buy" rating to a "hold" rating in a research note on Thursday, September 8th.

Medpace Price Performance

Medpace (NASDAQ:MEDP – Get Rating) last posted its quarterly earnings data on Monday, July 25th. The company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.12. The company had revenue of $351.21 million during the quarter, compared to analysts' expectations of $344.01 million. Medpace had a return on equity of 30.56% and a net margin of 16.27%. Medpace's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.06 earnings per share. On average, equities analysts predict that Medpace Holdings, Inc. will post 6.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MEDP. Point72 Hong Kong Ltd acquired a new position in shares of Medpace during the second quarter worth about $42,000. Signaturefd LLC boosted its position in Medpace by 486.7% during the first quarter. Signaturefd LLC now owns 264 shares of the company's stock valued at $43,000 after purchasing an additional 219 shares during the last quarter. Lansing Street Advisors acquired a new position in Medpace during the first quarter valued at approximately $44,000. Prospera Financial Services Inc acquired a new position in Medpace during the first quarter valued at approximately $47,000. Finally, Parkside Financial Bank & Trust acquired a new position in Medpace during the second quarter valued at approximately $50,000. 83.97% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

(Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Articles

• Get a free copy of the StockNews.com research report on Medpace (MEDP)
• Two Fun Stocks The Insiders Are Buying
• Novavax Remains a Risk-On Stock in a Risk-Off Market
• General Mills: Superior Returns With Less Volatility
• 3 Defensive Stocks With 60-Year Dividend Hike Streaks
• 3 Airline Stocks Stuck in a Holding Pattern

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.